Vivos Therapeutics, Inc. (NASDAQ:VVOS) Sees Large Increase in Short Interest

Vivos Therapeutics, Inc. (NASDAQ:VVOS) was the recipient of a significant growth in short interest during the month of August. As of August 15th, there was short interest totalling 87,400 shares, a growth of 54.7% from the July 31st total of 56,500 shares. Currently, 2.7% of the shares of the stock are short sold. Based on an average daily volume of 61,100 shares, the short-interest ratio is currently 1.4 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Vivos Therapeutics stock. Armistice Capital LLC purchased a new position in Vivos Therapeutics, Inc. (NASDAQ:VVOS) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 57,000 shares of the company’s stock, valued at approximately $709,000. Armistice Capital LLC owned 4.29% of Vivos Therapeutics as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 26.35% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Ascendiant Capital Markets raised their target price on Vivos Therapeutics from $6.40 to $6.60 and gave the company a “buy” rating in a report on Tuesday, August 20th.

Vivos Therapeutics Stock Down 3.5 %

NASDAQ VVOS traded down $0.10 on Friday, hitting $2.79. The company’s stock had a trading volume of 6,478 shares, compared to its average volume of 121,565. The company’s 50-day moving average is $2.43 and its 200 day moving average is $3.04. The firm has a market cap of $9.49 million, a PE ratio of -0.26 and a beta of 7.74. Vivos Therapeutics has a 1-year low of $1.91 and a 1-year high of $48.79.

About Vivos Therapeutics

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.